Combination Therapy Target Identified for Leukemia
Researchers found that pairing drugs can better eliminate chronic lymphocytic leukemia cells in lab models.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Do you believe developing new combination cancer therapies is the best way to improve patient survival?
Scientists have discovered that B-cell receptor (BCR) inhibitors cause leukemia cells to increase production of the CXCR4 receptor. Combining these inhibitors with the antibody ulocuplumab significantly improved the destruction of these cancer cells in laboratory and mouse studies.
Why it matters
Identifying treatment-induced changes in cancer cells offers a path toward more effective combination therapies for chronic lymphocytic leukemia. By targeting the CXCR4 receptor, doctors may one day improve how these existing treatments perform against resistant cells.
In a preclinical study published in HemaSphere, researchers used patient-derived leukemia cells to test therapy combinations. The results showed that targeting CXCR4 receptors with ulocuplumab improved the cell-killing efficacy of BCR inhibitors compared to drug monotherapy.
The players
CEITEC Masaryk University
A research center in Brno focusing on advanced science and biotechnology.
University Hospital Brno
A medical facility that contributed patient samples and research expertise to the study.
Dana-Farber Cancer Institute
A Boston-based cancer research and treatment center dedicated to finding new leukemia therapies.
The details
BCR inhibitors often trigger a compensatory increase in CXCR4 receptor abundance on the surface of chronic lymphocytic leukemia cells, which helps the cells survive. Ulocuplumab functions as an anti-CXCR4 antibody that blocks this pathway. By using this antibody to intercept the receptor, the treatment disrupts the survival signaling that normally allows the leukemia cells to persist despite the presence of BCR inhibitors.
Timeline
The study findings were published on October 8, 2026.
Health Landscape
BCR inhibitors have revolutionized the treatment of chronic lymphocytic leukemia by interfering with the signals cells need to survive. This new research marks a shift toward optimizing these therapies by identifying and blocking the adaptive resistance mechanisms that cancer cells develop.
This study highlights an experimental laboratory finding and does not change current treatment protocols for patients. If you are undergoing leukemia treatment, discuss any questions about ongoing research or therapy adjustments with your hematologist or oncologist.
The takeaway
Targeting the CXCR4 receptor may help overcome the survival signals that allow leukemia cells to resist BCR inhibitors. Patients should continue to follow their prescribed treatment plans and maintain regular checkups with their specialist team.
Further reading
For more on evolving approaches to managing blood-based malignancies, visit the Cancer section.
Source note: This article includes information reported by Central European Institute of Technology.
Live Poll
Do you believe developing new combination cancer therapies is the best way to improve patient survival?
